CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Jonathan Lieber as Chief Financial Officer. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.
Mr. Lieber is a seasoned financial executive with almost 30 years of experience in financial and executive management roles at emerging and growth-stage life sciences companies. As a Chief Financial Officer, Mr. Lieber has helped raise more than $400 million of equity and debt in public and private offerings, including a $110 million initial public offering at Altus Pharmaceuticals, and led myriad strategic and business development transactions, including the successful sale of Xcellerex to GE Healthcare.
Previously, Mr. Lieber worked as an investment banker for almost 10 years, during which time he originated and executed on numerous corporate financings and M&A transactions at SG Cowen and Salomon Brothers. Mr. Lieber earned a B.S. in Business Administration and Finance from Boston University and was awarded a M.B.A. in Finance from New York University Stern School of Business.
“We are pleased to have an accomplished finance executive of Jon’s caliber join Cognito Therapeutics. We welcome his deep operating and fundraising experience at biopharmaceutical companies and his strong investor and banking relationships,” said Brent Vaughan, Chief Executive Officer of Cognito Therapeutics. “As we build our presence with key investors, Jon brings invaluable experience as our CFO, and will lead our investor relations programs and our fundraising efforts as we advance towards our next stage of growth.”
“I am pleased to be joining Cognito Therapeutics at such an exciting time and look forward to working with the leadership team to advance the Company’s disease-modifying platform for neurodegenerative diseases, said Jonathan Lieber, Chief Financial Officer, Cognito Therapeutics. “With the recent FDA Breakthrough Designation and positive Phase 2 data, Cognito is well positioned to advance the first disease-modifying therapeutic for Alzheimer’s, and a pipeline of innovative neuromodulation treatments for significant unmet medical needs.”
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have shown drug-like effects to treat neurodegenerative disorders including Alzheimer’s disease. The company’s licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive, neurostimulation therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases. The company is based in Boston and San Francisco. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
